Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06265727 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
A Phase 1 study of Solid Tumor, Adult, sponsored by Corbus Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 348
- Enrollment target
- 20
- Study locations
NCT06265727: Recruiting Phase 1 study of Solid Tumor, Adult, sponsored by Corbus Pharmaceuticals.
NCT06265727 is a Phase 1 study of Solid Tumor, Adult that is actively recruiting participants, run by Corbus Pharmaceuticals. The registered enrollment target is 348 participants, above the 186-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (87% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06265727, a Phase 1 study of Solid Tumor, Adult, is actively recruiting participants, sponsored by Corbus Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 348 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical trial is to define a safe and effective dose of CRB-701 for participants with solid tumors that are expressing a protein called nectin-4. The main questions it aims to answer are: What is the the safe and effective dose of CRB-701? What cancers can be treated effectively with CRB-701? Participants will be asked to attend clinic and be given a intravenous infusion of CRB-701. They will have blood tests, CT or MRI Scans, and other assessments to measure whether CRB-701 has an effect on tumors.
Primary Outcome
Occurrence of Dose Limiting Toxicities as defined in the protocol
Conditions Studied
Interventions
- DRUG CRB-701
- DRUG Anti-PD-1
Study Locations (20)
Other
- ICM-Val d'Aurelle - Montpellier
- CHU de Poitiers - Poitiers
- Institut de Cancerologie de l'Ouest - Saint-Herblain
- Gustave Roussy - Villejuif
- Careggi University Hospital - Florence
California
- City of Hope Cancer Center - Duarte
- Moores Cancer Centre at UC San Diego Health - San Diego
- Helen Diller Family Comprehensive Cancer Center - UCSF - San Francisco
Illinois
- University of Chicago - Chicago
- Hope and Healing Cancer Center - Hinsdale
Alabama
- O'Neal Comprehensive Cancer Center at University of Alabama-Birmingham - Birmingham
Colorado
- Rocky Mountain Cancer Centres - Denver
Connecticut
- Yale Cancer Center - New Haven
Florida
- Florida Cancer Specialists - Orlando
Massachusetts
- Dana-Faber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 348 participants |
| Start Date | 2024-04-01 |
| Est. Completion | 2027-01-27 |
| Phase | Phase 1 |
What NCT06265727 shows while recruiting
NCT06265727 is an interventional study that assigns participants to a tested intervention. The registered 348 participants enrollment target is mid-sized for trials with a published cap, above the 186-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (87% higher).
The record links to 1 condition, with Solid Tumor, Adult appearing as the primary indexed condition, and to 2 interventions - of which CRB-701 is the first listed.
NCT06265727 names 20 study sites across 13 states, led by Other, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT06265727 about?
NCT06265727 is a clinical study titled "A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors". The goal of this clinical trial is to define a safe and effective dose of CRB-701 for participants with solid tumors that are expressing a protein called nectin-4. The main questions it aims to answer are: What is the the safe and effective dose of CRB-701? What cancers can be treated effectively ...
What is the current status of trial NCT06265727?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 348 participants. The study started on 2024-04-01. Estimated completion is 2027-01-27.
What conditions does trial NCT06265727 study?
This clinical trial studies the following conditions: Solid Tumor, Adult.
What interventions are being tested in trial NCT06265727?
The interventions under investigation include: CRB-701 (DRUG), Anti-PD-1 (DRUG).
Who is sponsoring clinical trial NCT06265727?
This trial is sponsored by Corbus Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06265727 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor, Adult
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06265727's enrollment target sits among peer trials
348 12th of 72 higher than 61 of 72 other Solid Tumor, Adult trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor, Adult trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04041479 · 348 participants · Phase 3
Biomarker-guided rTMS for Treatment Resistant Depression
- NCT04530565 · 348 participants · Phase 3
Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
- NCT05428735 · 348 participants · NA
The DRAGON 2 Trial
- NCT05787379 · 348 participants · NA
Care for Veterans Post-COVID-19
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI